Avelox® information for Healthcare Professionals

Avelox® Product Overview

The version of Flash player on this machine is either missing or out of date. Please update flash player to see the video.

Video 1 Avelox® Mode of Action

Avelox® (moxifloxacin) is a fourth generation synthetic fluoroquinolone antibiotic agent. It has in vitro activity against a wide range of Gram-positive, Gram-negative, atypical and anaerobic pathogens. The bactericidal action of Avelox® results from the inhibition of both type II topoisomerases (DNA gyrase and topoisomerase IV) required for bacterial DNA replication, transcription and repair. Pharmacodynamic investigations have demonstrated that moxifloxacin exhibits a concentration dependent killing rate.

Avelox® * 400mg film-coated tablets are indicated for the treatment of community acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS),complicated skin and skin structure infections (cSSSI), pelvic inflammatory disease (PID), and complicated intra-abdominal infections (cIAI).

Avelox® * 400mg intravenous (IV) formulation is indicated for the treatment of bacterial CAP, cSSSI, and cIAI.

The recommended dose for Avelox® oral film-coated tablets or IV solution for infusion is 400mg once daily (od) for all indications. The duration of therapy and route of administration is dependent upon the type and severity of infection (please see the Administration for further details).

The following adverse events have been commonly (>1/100, <1/10) reported during therapy with Avelox® 400mg (oral and sequential therapy): mycotic superinfections; headache; dizziness; QT prolongation in patients with hypokalaemia; nausea; vomiting; gastrointestinal and abdominal pains; diarrhoea; increase in transaminases; injection and infusion site reactions (IV only).

Avelox® is contraindicated in the following patients * :

  • Patients with hypersensitivity to moxifloxacin, other quinolones or to any of the excipients
  • Patients who are pregnant or lactating
  • Patients below 18 years of age

For further information regarding the safety profile of Avelox®, as well as drug interactions, please see the Safety page.

* Contraindications and licensed indications may vary from country to country, please ensure you consult your local prescribing information before prescribing Avelox®.

For further information on using Avelox® in the management of bacterial infections, please consult your local country specific prescribing information.

Avelox® Man - Circles of success